SCHEMBL2853429

SCHEMBL2853429

COc1ccccc1C(=O)NC(c1ccccc1)C1CCC(NS(=O)(=O)N2CCCN(C(C)=O)CC2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
KCNA5 P22460 1/20 0.44
ALDH1A1 P00352 5/20 0.42
KMT2A Q03164 5/20 0.42
MEN1 O00255 4/20 0.42
POLB P06746 1/20 0.42
MAPK1 P28482 1/20 0.42
HPGD P15428 2/20 0.42
HTT P42858 1/20 0.41
ATM Q13315 1/20 0.41
CDK1 P06493 1/20 0.41
CDK4 P11802 1/20 0.41
CCND1 P24385 1/20 0.41
CDK2 P24941 1/20 0.41
TSHR P16473 1/20 0.40
TP53 P04637 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2857658 0.86 KMT2A (0.55) MAPTKCNA5ALDH1A1KMT2AMEN1
SCHEMBL2854756 0.85 KCNA5 (0.49) MAPTKCNA5ALDH1A1KMT2AMEN1
SCHEMBL2857096 0.85 HPGD (0.48) MAPTLMNAKCNA5ALDH1A1KMT2A
SCHEMBL2858832 0.84 KCNA5 (0.45) MAPTKCNA5ALDH1A1KMT2AMEN1
SCHEMBL2878387 0.84 KCNA5 (0.46) KCNA5ALDH1A1KMT2AMEN1POLB
SCHEMBL2867485 0.83 KCNA5 (0.47) KCNA5ALDH1A1KMT2AMEN1POLB
SCHEMBL2867561 0.83 MAPT (0.52) MAPTLMNAKCNA5ALDH1A1KMT2A
SCHEMBL2861504 0.82 ALDH1A1 (0.47) MAPTKCNA5ALDH1A1KMT2AMEN1
SCHEMBL2858407 0.80 KCNA5 (0.44) KCNA5ALDH1A1KMT2AMEN1POLB
SCHEMBL5348976 0.79 KCNA5 (0.42) KCNA5ALDH1A1KMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2253328-A1 Cycloalkyl inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-11-24 EP disclosed
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-20050234106-A1 Cycloalkyl inhibitors of potassium channel function LLOYD JOHN 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234106-A1 Cycloalkyl inhibitors of potassium channel function KCNJ2, KCNN3, KCNQ5 MAPT 3616/4885LMNA 1535/4885KCNA5 23/4885
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNN3, KCNQ5 MAPT 3616/4885LMNA 1535/4885KCNA5 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.